World's Best Scientists 2026 revealed!
Jacob Schachter

Jacob Schachter

D-Index & Metrics

Biology and Biochemistry

D-Index
69
Citations
32993
World Ranking
7224
National Ranking
63

Overview

Jacob Schachter is affiliated with Sheba Medical Center in Israel. Their research primarily spans the fields of Medicine and Biochemistry, Genetics and Molecular Biology, with a strong focus on subfields such as Oncology, Molecular Biology, Immunology, Epidemiology, and Electrical and Electronic Engineering.

The scientist's work covers several main topics, including:

  • CAR-T cell therapy research
  • Cancer Immunotherapy and Biomarkers
  • Melanoma and MAPK Pathways
  • Immunotherapy and Immune Responses
  • Cutaneous Melanoma Detection and Management
  • Nonmelanoma Skin Cancer Studies
  • Immune Cell Function and Interaction

Jacob Schachter has contributed to a variety of research papers in prominent journals. Recent publications include:

  • Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients, 2020, Science
  • Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma, 2020, New England Journal of Medicine
  • Identification of bacteria-derived HLA-bound peptides in melanoma, 2021, Nature
  • Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial, 2021, The Lancet Oncology
  • Pembrolizumab Monotherapy for Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: A Single-Arm Phase II Trial (KEYNOTE-629), 2020, Journal of Clinical Oncology

Frequent coauthors of Jacob Schachter include:

  • Georgina V. Long
  • Caroline Robert
  • Jean-Jacques Grob
  • Laurent Mortier
  • Ana Arance

The scientist often publishes in venues such as:

  • Journal of Clinical Oncology
  • Annals of Oncology
  • Cancer Research
  • The Lancet Oncology
  • Journal for ImmunoTherapy of Cancer

Best Publications

  • Pembrolizumab versus Ipilimumab in Advanced Melanoma

    Caroline Robert;Caroline Robert;Caroline Robert;Jacob Schachter;Georgina V. Long;Ana Arance

  • Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib

    Caroline Robert;Boguslawa Karaszewska;Jacob Schachter;Piotr Rutkowski

  • Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

    Antoni Ribas;Igor Puzanov;Reinhard Dummer;Dirk Schadendorf

  • Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients

    Erez N. Baruch;Erez N. Baruch;Ilan Youngster;Guy Ben-Betzalel;Rona Ortenberg

  • Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma

    G. V. Long;A. Hauschild;M. Santinami;V. Atkinson

  • Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma.

    Caroline Robert;Jean J Grob;Daniil Stroyakovskiy;Boguslawa Karaszewska

  • Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma

    Antoni Ribas;Richard Kefford;Margaret A. Marshall;Cornelis J.A. Punt

  • Clinical Responses in a Phase II Study Using Adoptive Transfer of Short-term Cultured Tumor Infiltration Lymphocytes in Metastatic Melanoma Patients

    Michal J. Besser;Ronnie Shapira-Frommer;Avraham J. Treves;Dov Zippel

  • Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer : a European organization for research and treatment of cancer randomized study with cross-over

    Robert Paridaens;L. Biganzoli;P. Bruning;J.G.M. Klijn

  • Adoptive Transfer of Tumor-Infiltrating Lymphocytes in Patients with Metastatic Melanoma: Intent-to-Treat Analysis and Efficacy after Failure to Prior Immunotherapies

    Michal J. Besser;Ronnie Shapira-Frommer;Orit Itzhaki;Avraham J. Treves

  • Identification of bacteria-derived HLA-bound peptides in melanoma

    Shelly Kalaora;Adi Nagler;Deborah Nejman;Michal Alon

  • Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma

    Reinhard Dummer;Axel Hauschild;Mario Santinami;Victoria Atkinson

  • Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma

    Paolo Antonio Ascierto;Pier Francesco Ferrucci;Rosalie Fisher;Michele Del Vecchio

  • Vemurafenib in patients with BRAF V600 mutated metastatic melanoma: an open-label, multicentre, safety study

    James Larkin;Michele Del Vecchio;Paolo A Ascierto;Ivana Krajsova

  • Proteomics of Melanoma Response to Immunotherapy Reveals Mitochondrial Dependence

    Michal Harel;Rona Ortenberg;Rona Ortenberg;Siva Karthik Varanasi;Kailash Chandra Mangalhara

  • Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma.

    Mario Sznol;Pier Francesco Ferrucci;David Hogg;Michael B Atkins

  • Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial

    Jean Jacques Grob;Mayur M Amonkar;Boguslawa Karaszewska;Jacob Schachter

  • Final Results of Phase III SYMMETRY Study: Randomized, Double-Blind Trial of Elesclomol Plus Paclitaxel Versus Paclitaxel Alone As Treatment for Chemotherapy-Naive Patients With Advanced Melanoma

    Steven J. O'Day;Alexander M.M. Eggermont;Vanna Chiarion-Sileni;Richard Kefford

  • Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600–Mutant Stage III Melanoma

    Axel Hauschild;Reinhard Dummer;Dirk Schadendorf;Dirk Schadendorf;Mario Santinami

  • Selumetinib in Combination With Dacarbazine in Patients With Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT)

    Richard D. Carvajal;Sophie Piperno-Neumann;Ellen Kapiteijn;Paul B. Chapman

Frequent Co-Authors

Gal Markel
Gal Markel Tel Aviv University
Georgina V. Long
Georgina V. Long University of Sydney
Caroline Robert
Caroline Robert University of Paris-Saclay
Antoni Ribas
Antoni Ribas University of California, Los Angeles
James Larkin
James Larkin Royal Marsden NHS Foundation Trust
Axel Hauschild
Axel Hauschild Kiel University
Dirk Schadendorf
Dirk Schadendorf University of Duisburg-Essen
Jean-Jacques Grob
Jean-Jacques Grob Aix-Marseille University
Reinhard Dummer
Reinhard Dummer University of Zurich
Matteo S. Carlino
Matteo S. Carlino University of Sydney

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring Biology and Biochemistry can open up a wide range of career opportunities in healthcare, research, and industry. For those interested in clinical nutrition or wellness, pursuing the fastest nutrition degree may provide a quicker pathway into the workforce, allowing for a more flexible study schedule and faster completion rates.

Advancing into leadership or administrative roles within healthcare is also a popular option. Students who want to expand their business skills may consider the healthcare mba cost to identify programs that balance affordability with high ROI.

Healthcare informatics and medical coding offer alternative career pathways that combine science with technology. Understanding the distinction between a certified coding specialist (ccs) and other credentials is important; read more about certified coding specialist (ccs) qualifications, costs, and salary prospects.

For those who enjoy detail-oriented work and data management, a career in medical coding could be ideal. Discover the necessary steps to enter the field, along with medical.coder salary trends and growth potential in this expanding sector.

Best Scientists Citing Jacob Schachter

Trending Scientists

Recently Published Articles